Treatment options of invasive fungal infections in adults

Swiss Medical Weekly

Volumn 136, Issue 29-30, 2006, Pages 447-463

  Flückiger, Ursula ^a   Marchetti, Oscar ^b   Bille, Jacques ^b   Eggimann, Philippe ^b   Zimmerli, Stefan ^c   Imhof, Alexander ^d   Garbino, Jorge ^e   Ruef, Christian ^d   Pittet, Didier ^e   Täuber, Martin ^c   Glauser, Michel ^b   Calandra, Thierry ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antifungal agents; Candida; Guidelines; Invasive aspergillosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MICAFUNGIN; OMEPRAZOLE; POLYENE; POSACONAZOLE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STATINE DERIVATIVE; TACROLIMUS; VORICONAZOLE;

ADD ON THERAPY; ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EMPIRICAL RESEARCH; FEVER; FOOD DRUG INTERACTION; HALLUCINATION; HEALTH CARE PERSONNEL; HEPATITIS; HUMAN; HYPOTENSION; HYPOXEMIA; KIDNEY DISEASE; LIVER FUNCTION TEST; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PHLEBITIS; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RIGOR; SEPSIS; SEPTIC SHOCK; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

EID: 33747110733     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 2001;126:397-414.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
3. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess lenght of stay. Arch Intern Med 1988;148:2642-5.
4. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
5. Rentz AM, Halpern MT, Bowden RA. The impact of candidemia on lenght of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-8.
6. Gudlaugsson O, Gillespie S, Lee K, Vande BJ, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7.
7. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
8. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
9. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
10. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
11. Offner F, Krcmery V, Boogaerts M, Doyen C, Engelhard D, Ribaud P, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother 2004;48:4808-12.
12. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51.
13. Patel M, Kunz DF, Trivedi VM, Jones MG, Moser SA, Baddley JW. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn Microbiol Infect Dis 2005;52:29-34.
14. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20.
15. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4.
16. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-44.
17. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
18. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
19. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;1:1437-40.
20. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
21. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. Arch Intern Med 1989;149:2349-53.
22. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997;24:1068-78.
23. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
24. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
25. Viscoli C, Girmenia C, Marinus A, Colette L, Martino P, Vandercam B, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
26. White MH. Editorial response: the contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 1997;24:1129-30.
27. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-30.
28. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
29. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a mulocenter prospective study of candidemia. Antimicrob Agents Chemother 1999;43:1289-90.
30. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:3171-7.
31. Rex JH, Pfaller MA, Galgiani JN, Bartlett JA, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive break-points for antifungal susceptibility testing: conceptual frame-work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997;24:235-47.
32. Baddley JW, Patel M, Jones M, Cloud G, Smith AC, Moser SA. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis 2004;50:119-24.
33. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309-21.
34. Munoz P, Fernandez-Turegano CP, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E. Frequency and clinical significance of bloodstream infections caused by C albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect Dis 2002;44:163-7.
35. Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, et al. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother 2000;6:216-21.
36. Lee SC, Fung CP, Huang JS, Tsai CJ, Chen KS, Chen HY, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000;44:2715-8.
37. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993;12:911-5.
38. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie E. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998;42:129-34.
39. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
40. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005;41:975-81.
41. Nguyen MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995;155:2429-35.
42. Nolla-Salas J, Sitges-Serra AL-GC, Martinez-Gonzales J, Leonb-Regodir M, Ibanez-Lucia P, Torres-Rodriguez J, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factots and assessment of systemic antifungal therapy. Intensive Care Med 1997;23:23-30.
43. Morrell M, Fraser VJ, Kollef MH. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. Antimicrob Agents Chemother 2005;49:3640-5.
44. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, De Pauw BE, Filler SG, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997;25:43-59.
45. Rex JH, Walsh TJ, Sobel J, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-78.
46. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-82.
47. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002;132:316-20.
48. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003;36:943-51.
49. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004;54:803-8.
50. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-34.
51. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:1452-9.
52. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
53. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003;37:415-25.
54. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(Suppl 2):S133-S144.
55. Barrett JP, Vardulaki KA, Conlon C, Cooke J, za-Ramirez P, Evans EG, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-320.
56. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
57. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998;26:461-7.
58. Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28:223-6.
59. Lopez Sastre JB, Goto Cotallo GD, Fernandez CB. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20:153-63.
60. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE Jr, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
61. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
62. Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Hodges M, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54.
63. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, Dupont B, Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.
64. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42.
65. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharmaceutical Sciences 2004;21:645-53.
66. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22.
67. Skiest DJ, Vazquez JA, Graybill JR, Reynes J, Ward D, Corcoran GR, et al. Open-label trial of posaconazole for azole-refractory oropharyngeal ans oesophageal candidiasis in HIV/AIDS subjects: final analysis. 44th ICAAC, Washington D C 2004;Abs # M-1027.
68. Raad I, Chapman SW, Bradsher R, Morrison VA, Goldman M, Graybill JR, et al. Posaconazole salvage therapy for invasive fungal infections. 44th ICAAC, Washington D C 2004;Abs # 669.
69. Graybill JR, Raad I, Negroni R, Corcoran GR, Pedicone L. Posaconazole long-term safety in subjects with invasive fungal infections. 44th ICAAC, Washington D C 2004;Abs # M-1025.
70. Villanueva A, Arathoon E, Gotuzzo E, Berman R, DiNubile M, Sable C. A randomized double-blind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
71. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9.
72. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-7.
73. Mora-Duarte J, Betts R, Rotstein C, Lopes-Colombo A, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
74. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9.
75. Krause DS, Simjee AE, van RC, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770-5.
76. Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-9.
77. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61.
78. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021-4.
79. Reboli A, Rotstein C, Pappas PG, Schranz J, Krause D, Walsh T, et al. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis. 45th ICAAC Washington D C 2005;Abs. # M-718.
80. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987;33:381-95.
81. Thaler M, Bacher J, O'Leary T, Pizzo PA, Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis 1988;158:80-8.
82. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 2003;6:257-69.
83. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979;301:126-31.
84. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8.
85. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984;6:791-801.
86. Goldman M, Pottage JC Jr, Weaver DC. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine (Baltimore) 1993;72:143-50.
87. Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996;24:426-32.
88. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7.
89. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21.
90. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990;113:183-7.
91. Pahls S, Schaffner A. Aspergillus fumigatus pneumonia in neutropenic patients receiving fluconazole for infections due to Candida species: is amphotericin B combined with fluconazole the appropriate answer? Clin Infect Dis 1994;18:484-6.
92. Schaffner A, Frick PG. The effect of ketokonazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985;151:902-10.
93. Sanati H, Ramos CF, Bayer AS, Ghannoum MA. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother 1997;41:1345-8.
94. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8.
95. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrobial Agents & Chemotherapy 2000;44:2932-8.
96. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005;50:443-9.
97. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380-5.
98. Drago M, Scaltrito MM, Morace G. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004;23:619-24.
99. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
100. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000;31:545-53.
101. Denning DW. Aspergillosis in "nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 2004;170:580-1.
102. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van WE. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004;170:621-5.
103. Ascioglu S, Rex JH, De Pauw BE, Bennet JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
104. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250-60.
105. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, et al. Aspergillus terreus: an emerging amphotericin B-resistant oppornmistic mold in patients with hematologic malignancies. Cancer 2004;101:1594-600.
106. Espinel-Ingroff A, Bartlett M, Bowden R, Chin NX, Cooper C Jr, Fothergill A, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997;35:139-43.
107. Espinel-Ingroff A. Clinical utility of in vitro antifungal susceptibility testing. Rev Esp Quimioter 2000;13:161-6.
108. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002;40:2101-7.
109. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003;41:403-9.
110. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
111. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005;41:1448-52.
112. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
113. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
114. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-60.
115. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-8.
116. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66.
117. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-12.
118. Cornely OA, Maertens J, Bresnik M, Herbrecht R and on behalf of the AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005;106:900a, Abstract 3222 (ASH 2005).
119. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994;97:135-44.
120. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice H, Seifert WF, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematological malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-e90.
121. Utili R, Zampino R, De VF, Maiello C, Andreana A, Mormone G, et al. Improved outcome of pulmonary aspergillosis in heart transplant recipients with early diagnosis and itraconazole treatment. Clin Transplant 2000;14:282-6.
122. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
123. Herbrecht R, Denning DW, Patterson TF, Bennet JE, Greenfield LD, Oestmann J, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
124. Anonymous.FDA ADAC. Briefing document for voriconazole. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_0 1_Pfizer pdf 2001;
125. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540-7.
126. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587-8.
127. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-72.
128. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241-4.
129. Pascual A, Bolay S, Marchetti O. Monitoring of Voriconazole Blood Levels: 1-Year Experience at a University Hospital. 45th ICAAC New Orleans 2005;Abs. # M-2164.
130. Alexander B, Perfect JR, Daly J, Restrepo A, Tobon A, Patino H, et al. Posaconazole as salvage therapy in patients with invasive fungal infections following solid-organ transplant. 45th ICAAC Washington D C 2005;Abs # M-959.
131. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo S, et al. Posaconazole versus fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. 45th ICAAC Washington D C 2005;Abs # M-716.
132. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-71.
133. Candoni A, Mestroni R, Damiani D, Tiribelli M, Michelutti A, Silvestri F, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005;75:227-33.
134. Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology (Williston Park) 2004;18:24-9.
135. Cuenca-Estrella M. Combinations of antifungal agents in therapy - what value are they? J Antimicrob Chemother 2004;54:854-69.
136. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292-9.
137. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
138. Maertens J, Glasmacher A, Herbrecht R, Aoun M, Thiébaut A, Cordonnier C, et al. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final data. 45th ICAAC Washington D C 2005;Abs. # M-954.
139. Singh N, Limaye A, Safdar N, Forrest G, Pursell K, Munoz P, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients. 45th ICAAC Washington D C 2005;Abs. # M-717.
140. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
141. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
142. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:11-5.
143. van't Wout JW, Novakova I, Verhagen CA, Fibbe WE, De Pauw BE, van der Meer JW. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
144. Walsh TJ, Rubin M, Hathorn J, Gress J, Thaler M, Skelton J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med 1991;151:765-70.
145. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994;33:603-13.
146. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814-20.
147. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-8.
148. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105:478-83.
149. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
150. Silling G, Fegeler W, Roos N, Essink M, Buchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999;42(Suppl 2):101-4.
151. Nucci M, Loureiro M, Silveira F, Casali AR, Bouzas LF, Velasco E, et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother 1999;43:1445-8.
152. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63.
153. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9.
154. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20.
155. Boogaerts M, Winston DJ, Bow E, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001;135:412-22.
156. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
157. Subira M, Martino R, Gomez L, Marti JM, Estany C. Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol 2004;72:342-7.
158. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.